Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, United States
Kara L Conway
Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, United States
Broad Institute of Harvard and MIT, Cambridge, United States; Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, United States
Humberto B Jijon
Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, United States
Hui Pan
Joslin Diabetes Center, Boston, United States
Eunyoung Chun
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, United States
Monia Michaud
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, United States
Jessica K Lang
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, United States
Carey Ann Gallini Comeau
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, United States
Jonathan M Dreyfuss
Joslin Diabetes Center, Boston, United States
Jonathan N Glickman
Department of Pathology, Harvard Medical School, Boston, United States; Beth Israel Deaconess Medical Center, Boston, United States
Hera Vlamakis
Broad Institute of Harvard and MIT, Cambridge, United States
Ashwin Ananthakrishnan
Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, United States
Aleksander Kostic
Joslin Diabetes Center, Boston, United States; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, United States
Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, United States; Broad Institute of Harvard and MIT, Cambridge, United States; Department and Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States
Ramnik J Xavier
Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, United States; Broad Institute of Harvard and MIT, Cambridge, United States
Inflammatory bowel disease (IBD) is driven by dysfunction between host genetics, the microbiota, and immune system. Knowledge gaps remain regarding how IBD genetic risk loci drive gut microbiota changes. The Crohn’s disease risk allele ATG16L1 T300A results in abnormal Paneth cells due to decreased selective autophagy, increased cytokine release, and decreased intracellular bacterial clearance. To unravel the effects of ATG16L1 T300A on the microbiota and immune system, we employed a gnotobiotic model using human fecal transfers into ATG16L1 T300A knock-in mice. We observed increases in Bacteroides ovatus and Th1 and Th17 cells in ATG16L1 T300A mice. Association of altered Schaedler flora mice with B. ovatus specifically increased Th17 cells selectively in ATG16L1 T300A knock-in mice. Changes occur before disease onset, suggesting that ATG16L1 T300A contributes to dysbiosis and immune infiltration prior to disease symptoms. Our work provides insight for future studies on IBD subtypes, IBD patient treatment and diagnostics.